---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-101819"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:28:50.449105+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Sagimet updates investor presentation highlighting MASH, acne, and cancer pipeline

## Summary
- Presentation dated October 23, 2025, targets metabolic dysfunction with novel therapies for MASH, acne, and cancer.
- Management will use the updated deck in investor meetings; specific data or milestones not disclosed in filing excerpt.
- No financial results, guidance changes, or clinical trial readouts included in the furnished exhibit (title page only).

## SEC filing metadata
- accession: 0001104659-25-101819
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465925101819/0001104659-25-101819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465925101819/tm2529317d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-101819
- JSON: https://secwatch.observer/filing/0001104659-25-101819.json
- Plain text: https://secwatch.observer/filing/0001104659-25-101819.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.